본문 바로가기
KERD
논문KCI 등재

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea

San-Gang Wu|Jia-Yuan Sun|Zhen-Yu He|Juan Zhou|Jun-Jie Wang|Fengyan Li|Qin Lin|Huan-Xin Lin
대한암학회 (Korean Cancer Association)|2015.01|Cancer Research and Treatment|제47권 제1호|pp. 55-63|DOI http://dx.doi.org/10.4143/crt.2013.165

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Breast neoplasmsPremenopauseGoserelinOvarian ablationTherapy-induced amenorrhea
주제분류의학일반

초록

Purpose The purpose of this study was to assess the value of ovarian ablation using goserelin inpremenopausal patients with stage II/III hormone receptor-positive breast cancer withoutchemotherapy-induced amenorrhea (CIA). Materials and MethodsWe retrospectively reviewed the data of breast patients treated between October 1999 andNovember 2007 without CIA. The Kaplan-Meier method was used for calculation of thesurvival rate. Log rank method and Cox regression analysis were used for univariate andmultivariate prognostic analysis. ResultsThe median follow-up period was 61 months. Initially, 353 patients remained without CIAafter chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). Inunivariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9%vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006),disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5%vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independentfactor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311;95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantlyimproved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) inpatients aged < 40 years. In patients aged  40 years, goserelin only improved DMFS(p=0.028) and DFS (p=0.027). ConclusionOvarian ablation with goserelin plus TAM resulted in significantly improved therapeuticefficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancerwithout CIA.

Abstract

Purpose The purpose of this study was to assess the value of ovarian ablation using goserelin inpremenopausal patients with stage II/III hormone receptor-positive breast cancer withoutchemotherapy-induced amenorrhea (CIA). Materials and MethodsWe retrospectively reviewed the data of breast patients treated between October 1999 andNovember 2007 without CIA. The Kaplan-Meier method was used for calculation of thesurvival rate. Log rank method and Cox regression analysis were used for univariate andmultivariate prognostic analysis. ResultsThe median follow-up period was 61 months. Initially, 353 patients remained without CIAafter chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). Inunivariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9%vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006),disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5%vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independentfactor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311;95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantlyimproved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) inpatients aged < 40 years. In patients aged  40 years, goserelin only improved DMFS(p=0.028) and DFS (p=0.027). ConclusionOvarian ablation with goserelin plus TAM resulted in significantly improved therapeuticefficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancerwithout CIA.

참고문헌 (23)

  1. Li J, "A nation-wide multicenter 10-year(1999-2008)retrospective clinical epidemiological study of female breast cancer in China", BMC Cancer, 11, pp.364~ (2011)
  2. Han JG, "Clinicopathologic characteristics and prognosis of young patients with breast cancer", Breast, 20, pp.370~372 (2011)
  3. Peng R, "Patients 35years old or younger with operable breast cancer are more at risk for relapse and survival : a retrospective matched case-control study", Breast, 20, pp.568~573 (2011)
  4. Tan SH, "Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer", Clin Breast Cancer, 7, pp.455~464 (2007)
  5. Clarke MJ, "Ovarian ablation in breast cancer, 1896 to 1998 : milestones along hierarchy of evidence from case report to Cochrane review", BMJ, 317, pp.1246~1248 (1998)
  6. LHRH-agonists in Early Breast Cancer Overview Group, "Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer : a meta-analysis of individual patient data from randomised adjuvant trials", Lancet, 369, pp.1711~1723 (2007)
  7. Wu S, "Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor : a retrospective matched case-control study", Cancer Biother Radiopharm, 28, pp.697~702 (2013)
  8. Davidson NE, "Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer : results from INT 0101(E5188)", J Clin Oncol, 23, pp.5973~5982 (2005)
  9. Gnant M, "Endocrine therapy plus zoledronic acid in premenopausal breast cancer", N Engl J Med, 360, pp.679~691 (2009)
  10. Adjuvant Breast Cancer Trials Collaborative Group, "Ovarian ablation or suppression in premenopausal early breast cancer : results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial", J Natl Cancer Inst, 99, pp.516~525 (2007)
  11. Aebi S, "Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 22(Suppl 6), pp.12~24 (2011)
  12. Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
  13. Kaufmann M, "A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer-GABG-IV B-93", Eur J Cancer, 43, pp.2351~2358 (2007)
  14. Sverrisdottir A, "Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer", Breast Cancer Res Treat, 128, pp.755~763 (2011)
  15. Cheng TF, "Cost-utility analysis of adjuvant goserelin(Zoladex)and adjuvant chemotherapy in premenopausal women with breast cancer", BMC Cancer, 12, pp.33~ (2012)
  16. Karlsson P, "Long-term results of International Breast Cancer Study Group Trial VIII : adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer", Ann Oncol, 22, pp.2216~2226 (2011)
  17. Baum M, "Adjuvant goserelin in pre-menopausal patients with early breast cancer : results from the ZIPP study", Eur J Cancer, 42, pp.895~904 (2006)
  18. Pagani O, "Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement : results of the International Breast Cancer Study Group(IBCSG)Trial VI", Eur J Cancer, 34, pp.632~640 (1998)
  19. Goldhirsch A, "Adjuvant therapy for very young women with breast cancer : need for tailored treatments", J Natl Cancer Inst Monogr, 30, pp.44~51 (2001)
  20. Walshe JM, "Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer", J Clin Oncol, 24, pp.5769~5779 (2006)
  21. Arriagada R, "Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy", Ann Oncol, 16, pp.389~396 (2005)
  22. "National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Breast Cancer. Version 1"[URL]
  23. Regan MM, "Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?", Ann Oncol, 19, pp.1231~1241 (2008)

관련 논문AI추천

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor–Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors강은영, 김기동, 김세현, 김유정, 김은규, 김지현, 김태용, 김희승, 노동영, 노재홍, 서경진, 이경훈, 임석아, 한세원, 한원식, 이마리아대한암학회 · Cancer Research and Treatment2017 · 제49권 제4호Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer고범석, 김희정, 백승희, 손귀연, 손병호, 안세현, 이새별, 이유라, 이종원대한암학회 · Cancer Research and Treatment2016 · 제48권 제4호Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone- Releasing Hormone Agonist in Premenopausal Metastatic Breast CancerChan Sub Park, Hyun-Ah Kim, Jihye Choi, Min-Ki Seong, Sang Hee Kim, Woo Chul Noh한국유방암학회 · Journal of Breast Disease2018 · 제6권 제2호Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea김태용, 김태유, 노동영, 문형곤, 범승훈, 서경진, 양예원, 오도연, 오지수, 이경훈, 임석아, 한세원, 한원식대한암학회 · Cancer Research and Treatment2017 · 제49권 제2호Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer강은영, 김선미, 김세현, 김은규, 김지현, 박소연, 박예송, 서경진, 신희철, 윤경학, 윤보라, 장미정대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-analysis from Randomized Clinical Trials and Propensity Score Matching of Multicentre Cohort StudyChenchen Li, Dagui Lin, Guolin Ye, Herui Yao, Huangming Hong, Jianli Zhao, Jun Tang, Peixian Chen, Qiyun Ou, Quanlong Gao, Tuping Fu, Wei Ren, Xinxin Xie, Ying Wang, Yongjian Chen, Yujie Tan, Yunfang Yu대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호

이 간행물의 다른 논문 (14건)

Patient’s Factors at Entering Hospice Affecting Length of Survival in a Hospice Center안혜신, 이국진, 진종률, 김지현, 이구옥, 고세은, 양여리, 이미영, 강승헌, 전상훈, 서민우pp. 1-8Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children신상준, 노재경, 유철주, 한정우, 조용진, 김수희, 신규호, 안중배, 라선영, 정현철, 양우익, 김효송, 임선민pp. 9-17A Phase I/II Trial to Evaluate the Technical Feasibility of Partial Breast Irradiation with Three-Dimensional Conformal Radiation Therapy in Korean Women with Stage I Breast Carcinoma: An Initial eport of the Korean Radiation Therapy Oncology Group (KROG) Study 0804정재욱, 박민호, 윤정한, 서창옥, 안성자, 김용협, 송주영, 정웅기, 윤미선, 남택근pp. 18-25Prospective Evaluation of the Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Negative Axillary Conversion after Neoadjuvant Chemotherapy이해디, 이승아, 안성귀, 정준, 이학민pp. 26-33Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma김태현, 김보현, 김상수, 김주영, 김연주, 박중원, 이우진, 김대용, 문승호, 김창민, 고영환, 박상재, 우상명pp. 34-45
원문 보기